Doctors take on Highmark on office-visit drug co-pays
Pittsburgh Post-Gazette, March 7, 2008
Highmark Inc.'s recent decision to charge Medicare customers $25 co-payments on certain injected drugs--chemotherapy agents, immunosuppressants, anemia drugs--is becoming a financial burden to a number of customers who require such injections several times a week. A spokesman for Highmark said the new charges were needed to defray the rising cost of the injected drugs, which can run from $100 to $30,000 per dose, depending on the drug.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- CHS Hacked, 4.5M Patient Records Compromised